Free Trial

Chemours (CC) Expected to Announce Quarterly Earnings on Tuesday

Chemours logo with Basic Materials background

Key Points

  • Chemours is set to release its Q2 2025 earnings on August 5th, with analysts expecting earnings of $0.47 per share and $1.57 billion in revenue.
  • The company's shares recently fell 7.6%, trading at $12.56, and it has a market capitalization of $1.88 billion.
  • Insider transactions include significant stock purchases by CFO Shane Hostetter and other insiders, indicating confidence in the company's future performance.
  • Need better tools to track Chemours? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Chemours (NYSE:CC - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results after the market closes on Tuesday, August 5th. Analysts expect Chemours to post earnings of $0.47 per share and revenue of $1.57 billion for the quarter.

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The specialty chemicals company reported $0.13 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.06). Chemours had a return on equity of 23.82% and a net margin of 0.54%. The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same period in the prior year, the company earned $0.32 EPS. The firm's revenue was up .4% compared to the same quarter last year. On average, analysts expect Chemours to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Chemours Price Performance

NYSE:CC traded down $0.48 during mid-day trading on Friday, reaching $11.50. 4,054,112 shares of the company were exchanged, compared to its average volume of 3,758,767. The stock has a market cap of $1.72 billion, a PE ratio of 57.50 and a beta of 1.61. The company has a quick ratio of 0.83, a current ratio of 1.75 and a debt-to-equity ratio of 7.01. Chemours has a 12 month low of $9.13 and a 12 month high of $22.38. The company has a fifty day moving average of $12.02 and a 200 day moving average of $13.50.

Chemours Dividend Announcement

The firm also recently announced a dividend, which was paid on Monday, June 16th. Stockholders of record on Monday, May 19th were paid a $0.0875 dividend. This represents a dividend yield of 317.0%. The ex-dividend date of this dividend was Friday, May 16th. Chemours's dividend payout ratio (DPR) is 175.00%.

Insider Activity at Chemours

In related news, CFO Shane Hostetter bought 4,450 shares of the company's stock in a transaction on Monday, May 19th. The shares were purchased at an average cost of $11.28 per share, for a total transaction of $50,196.00. Following the acquisition, the chief financial officer owned 59,694 shares of the company's stock, valued at approximately $673,348.32. This represents a 8.06% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Damian Gumpel bought 7,822 shares of the company's stock in a transaction on Tuesday, June 3rd. The shares were bought at an average price of $9.95 per share, for a total transaction of $77,828.90. Following the completion of the acquisition, the insider directly owned 131,701 shares in the company, valued at approximately $1,310,424.95. This trade represents a 6.31% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 25,672 shares of company stock worth $251,573 over the last 90 days. Corporate insiders own 0.47% of the company's stock.

Hedge Funds Weigh In On Chemours

Several hedge funds have recently made changes to their positions in CC. Royal Bank of Canada boosted its position in Chemours by 6.8% during the first quarter. Royal Bank of Canada now owns 585,702 shares of the specialty chemicals company's stock worth $7,926,000 after purchasing an additional 37,382 shares during the period. Empowered Funds LLC bought a new position in Chemours during the first quarter worth $403,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Chemours by 149.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,243 shares of the specialty chemicals company's stock worth $593,000 after purchasing an additional 25,899 shares during the period. AQR Capital Management LLC acquired a new stake in shares of Chemours during the first quarter worth $161,000. Finally, Baird Financial Group Inc. acquired a new stake in shares of Chemours during the first quarter worth $148,000. 76.26% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

CC has been the topic of several recent research reports. Mizuho raised their target price on shares of Chemours from $13.00 to $16.00 and gave the company an "outperform" rating in a research note on Tuesday, July 15th. Wall Street Zen lowered shares of Chemours from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. The Goldman Sachs Group reduced their target price on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 14th. Truist Financial cut their price target on shares of Chemours from $27.00 to $22.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Finally, Morgan Stanley cut their price target on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a research report on Monday, May 12th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. According to MarketBeat, Chemours currently has a consensus rating of "Hold" and a consensus price target of $17.44.

Read Our Latest Stock Analysis on Chemours

About Chemours

(Get Free Report)

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

Further Reading

Earnings History for Chemours (NYSE:CC)

Should You Invest $1,000 in Chemours Right Now?

Before you consider Chemours, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.

While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Next Tech Boom: AI Robots Are Coming Sooner Than You Think!
Tech Stocks Stumble: Will Nvidia’s Report Spark a Rebound?
Follow the Money: 5 Stocks Institutions Are Buying NOW

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines